ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 154 filers reported holding ENANTA PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $1,507,757 | -67.8% | 40,507 | -59.7% | 0.01% | -68.8% |
| Q4 2022 | $4,675,367 | -10.3% | 100,507 | 0.0% | 0.03% | -13.5% |
| Q3 2022 | $5,214,000 | -3.7% | 100,507 | -12.2% | 0.04% | -17.8% |
| Q2 2022 | $5,412,000 | -33.6% | 114,507 | 0.0% | 0.04% | -18.2% |
| Q1 2022 | $8,150,000 | -32.5% | 114,507 | -29.0% | 0.06% | -28.6% |
| Q4 2021 | $12,066,000 | +66.7% | 161,358 | -9.8% | 0.08% | +28.3% |
| Q1 2021 | $7,236,000 | -4.0% | 178,941 | 0.0% | 0.06% | 0.0% |
| Q4 2020 | $7,534,000 | +157.0% | 178,941 | +179.4% | 0.06% | +114.3% |
| Q3 2020 | $2,931,000 | -55.9% | 64,034 | -41.9% | 0.03% | -62.2% |
| Q1 2020 | $6,652,000 | -2.2% | 110,139 | 0.0% | 0.07% | +1.4% |
| Q4 2019 | $6,804,000 | -1.5% | 110,139 | -4.2% | 0.07% | -20.7% |
| Q3 2019 | $6,909,000 | +26.5% | 115,000 | +76.9% | 0.09% | +35.3% |
| Q2 2019 | $5,461,000 | -12.0% | 65,000 | 0.0% | 0.07% | -13.9% |
| Q1 2019 | $6,209,000 | +41.4% | 65,000 | +4.8% | 0.08% | +17.9% |
| Q4 2018 | $4,391,000 | +203.0% | 62,000 | +396.0% | 0.07% | +191.3% |
| Q2 2018 | $1,449,000 | -26.9% | 12,500 | -49.0% | 0.02% | -32.4% |
| Q1 2018 | $1,982,000 | -50.3% | 24,500 | -64.0% | 0.03% | -50.7% |
| Q4 2017 | $3,990,000 | -62.1% | 68,000 | -69.8% | 0.07% | -62.5% |
| Q3 2017 | $10,530,000 | -5.6% | 225,000 | -27.4% | 0.18% | -12.4% |
| Q2 2017 | $11,154,000 | +1.7% | 310,000 | -12.9% | 0.21% | -0.9% |
| Q1 2017 | $10,965,000 | +38.7% | 356,000 | +50.8% | 0.21% | +17.1% |
| Q4 2016 | $7,906,000 | +22.8% | 236,000 | -2.5% | 0.18% | +16.8% |
| Q3 2016 | $6,440,000 | +36.1% | 242,000 | +49.4% | 0.16% | +31.4% |
| Q1 2016 | $4,732,000 | +35.2% | 162,000 | +52.8% | 0.12% | +25.5% |
| Q4 2015 | $3,500,000 | +72.8% | 106,000 | +135.6% | 0.09% | +123.8% |
| Q2 2015 | $2,025,000 | +13.8% | 45,000 | +28.6% | 0.04% | +13.5% |
| Q4 2014 | $1,780,000 | – | 35,000 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 858,811 | $36,156,000 | 10.56% |
| Fairmount Funds Management LLC | 150,433 | $6,333,000 | 2.26% |
| ARMISTICE CAPITAL, LLC | 1,356,000 | $57,088,000 | 1.94% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,775,000 | $74,728,000 | 0.45% |
| Virtus ETF Advisers LLC | 14,321 | $603,000 | 0.25% |
| Granahan Investment Management | 231,071 | $9,728,000 | 0.22% |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 248,320 | $10,454,000 | 0.09% |
| ACADIAN ASSET MANAGEMENT LLC | 467,514 | $19,684,000 | 0.08% |
| VIRTUS ALTERNATIVE INVESTMENT ADVISERS, INC. | 126 | $5,000 | 0.08% |
| AIGEN INVESTMENT MANAGEMENT, LP | 12,854 | $541,000 | 0.07% |